Clinical Trials Browser

Recruiting × NIH × Gemcitabine × Clear all

NCT04267848 2026-04-15

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06524544 2026-04-15

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT04628767 2026-04-14

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

Renal Pelvis and Ureter Urothelial Carcinoma

NCT03907475 2026-04-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Phase 2 Recruiting

Neoplasm Metastasis

NCT05685602 2026-04-13

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06029270 2026-04-13

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT06064097 2026-04-13

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT06498648 2026-04-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Phase 1/2 Recruiting

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT06050252 2026-04-03

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

Phase 2 Recruiting

Gastrointestinal

Resectable Intrahepatic Cholangiocarcinoma

NCT03606967 2026-04-02

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms